Opko Health, Inc. (OPK) · Oct 15, 2026 · Disposition

OPKO asset sale fetches $722M as BioReference exits diagnostics

$722M asset sale — $722M cash at closing plus up to $150M 4Kscore earnout

OPKO’s asset-sale agreement with Labcorp brings $722 million upfront and a possible $150 million 4Kscore earnout, but removes its remaining diagnostics platform.

OPKO is already shrinking BioReference after selling earlier oncology and clinical-testing assets to Labcorp; its remaining diagnostics story was centered on New York/New Jersey clinical testing, urology, corrections services and the 4Kscore prostate-cancer test, while the company increasingly frames itself around biopharmaceutical development. This filing completes that strategic exit on paper. OPKO will sell the remaining identified BioReference assets to Labcorp, including 4Kscore, for substantial upfront cash, rather than continue operating the laboratory platform itself. The transaction covers clinical and women’s health testing, urology, corrections and the proprietary 4Kscore test. 〔0〕

Transaction economics	Amount / timing
Cash paid at closing	$722 million, subject to revenue-based adjustment (Item 1.01)
Additional 4Kscore earnout	Up to $150 million over as long as 10 years (Item 1.01)
Regulatory termination fee	$28.88 million if specified approvals fail (Item 1.01)
Outside closing date	April 14, 2027, unless extended (Item 1.01)

The immediate business benefit is liquidity and simplification, not operating growth. The $722 million upfront payment gives OPKO a large cash resource and removes the burden of running a diagnostics business that had already been reduced through prior divestitures. The filing, however, does not say how OPKO will deploy the proceeds or quantify the profitability of the assets being sold, so the cash benefit cannot be cleanly translated into future earnings from this document alone. The deal is not subject to a financing condition. 〔1〕

The trade-off is the loss of a continuing diagnostics revenue stream and direct 4Kscore upside. OPKO receives only a contingent earnout for future 4Kscore revenue, capped at $150 million and spread over up to a decade, while Labcorp takes control of commercialization and operating execution. That makes the transaction economically meaningful but also confirms that OPKO is exchanging recurring operating exposure for cash and a narrower biopharma focus.

The transaction is signed, not closed. HSR clearance and other customary conditions remain outstanding, with an outside date of April 14, 2027. The $28.88 million regulatory termination fee offers some protection, but it does not eliminate closing or execution risk. 〔2〕

Bottom line: This is a major portfolio reset: OPKO monetizes and exits its remaining diagnostics operations, giving up an operating business in exchange for cash and a contingent 4Kscore payout. It materially advances the shift toward biopharma, but the filing does not yet show how that cash will create replacement growth or earnings.

What to watch next

HSR clearance and closing by April 14, 2027

Original filing on SEC EDGAR

More Opko Health, Inc. news

OPKO earnings: revenue edges past estimates as guidance gets withdrawn

Live · an AI on the whole US market

Breaking down Wall Street's information edge.

A buy-side analyst on every ticker.

It reads every public company's filing the second it drops — decoded into plain English, before it's a headline. The edge every investor deserves, not just the desks.

Trade the facts, not the FOMO.

Every event

8-Ks decoded the moment they file

Every number

Fundamentals, valuation, quality

What's next

Earnings calendar + the analyst view

scroll ↓

From filing to your screen in seconds

AllSight is the fastest.

DETECT

The moment it files

Every public company, around the clock. The AI never blinks and never takes lunch — nothing to set up.

filed 9:41:03 · decoded 9:41:19

DECODE

Plain English — never a call.

The event, the numbers, how it sits vs. expectations — in seconds. The AI decodes it; you pull the trigger.

DELIVER

On your screen, before the bell

Overnight and premarket, it's already read everything. You walk into every session with the setup — not scrambling to find it.

Understand it like a Wall Street analyst. Explained like a friend.

the raw filing — read the original on SEC.gov↗

decoded▸

AllSight · BlackBerry Q2 FY27

Revenue $163.3M vs ~$144M expected; adjusted basic EPS $0.07 vs ~$0.04 consensus — a real upside surprise.Income statement
QNX revenue +27% to $80.3M; segment EBITDA $29.0M from $20.5M. “Record performance… core automotive.”Segment — QNX
Licensing jumped to $22.1M from $6.6M — it amplified the beat, but it's less recurring than QNX, so the quality sits in QNX.Segment — Licensing
FY27 guide lifted to $616–636M rev / $141–158M EBITDA, above the prior $594–621M / $119–139M framework.Guidance
QNX growth, margins, cash and a raised outlook all beat. But licensing amplified it and Secure Comms is flat — net retention 91% from 93%.Segment — Secure Comms

Know a company all the way down.

Not just one filing. AllSight profiles every public company end to end — the numbers, the quality, the insiders, the smart money, the Street. One page, nothing missed.

Price & every insider trade, plotted
A quality score ranked against every peer
40+ valuation & profitability multiples
Where each one sits in its 5-year range
Whole-market insider flow, in real time
Which superinvestors are holding it
Analyst consensus & price target

Live · — filings read this week

AllSight gives you an edge others can't.

One scan before the open, one after the close — every filing on every ticker, already decoded. You walk into every session fully prepared.

Not investment advice · a neutral translation you can check against the original SEC filing

allsight.ai

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—

8-K events this week

—

filings analyzed in total

live · updated 30s ago

Live events · whole market · · --:--:-- ET

AllSight read

Events/ANDE/8-K · Earnings

8-K · Item 2.02 · Earnings

The Andersons — a record Renewables quarter that beat profit expectations

Filed Aug 3, 2026ANDE · NASDAQ

AllSight readBeatPriced in▲ 1.8% since filed · reaction agrees

adj. EPS $2.15 vs ~$1.48 consensus

This filing tests whether The Andersons' sharp profit increase reflects broad operating improvement or a one-off renewable-fuels boost. It also separates strong adjusted earnings and cash generation from the quarter's legal and impairment charges.

The quarter was substantially stronger than both last year and the published earnings expectation. Adjusted EPS reached $2.15, versus $0.24 a year earlier and above the published consensus of about $1.48; reported EPS was $1.65. Adjusted EBITDA more than doubled to $140 million, while sales slipped modestly — the improvement came from margins and operating performance rather than higher revenue. Financial Highlights · Statements of Operations

Q2 ($M, exc. per-share)	Q2 2026	Q2 2025	YoY
Sales & merchandising revenue	3,097.7	3,135.9	−1%
Net income (attributable)	56.6	7.9	+48.7
Diluted EPS	1.65	0.23	+1.42
Adjusted EPS	2.15	0.24	+1.91
Adjusted EBITDA	140.3	65.2	+75.1
Agribusiness adj. pretax	20.3	16.8	+3.5
Renewables adj. pretax	88.4	9.6	+78.8
Cash from operations	487.9	299.3	+188.6
Cash from ops (pre-WC)	112.9	42.9	+70.1

Renewables drove nearly all of the upside — the operating backdrop was strong, but the result also benefited materially from tax credits. Renewables' adjusted pretax income rose to $88 million on record production, stronger ethanol margins and merchandising gains. It also received $24 million of 45Z producer tax credits, so this was not solely a repeatable plant-margin improvement; the company did cite healthy export and domestic ethanol demand as supportive. Renewables — Record Q2 · Segment Data

Agribusiness improved, but it was a supporting contributor rather than the main earnings engine. Adjusted pretax income increased to $20 million as fertilizer margins improved and merchandising benefited from commodity-price volatility, despite lower fertilizer volumes. Agribusiness — Improved Q2 · Segment Data

Cash generation improved and funding capacity is comfortable, while reported earnings still absorbed meaningful non-core costs. Operating cash flow was $488 million ($113 million before working-capital changes); capital spending was $76 million. Adjusted EPS excludes $0.50 of legal-settlement, impairment and transaction items, so the $2.15 adjusted result runs ahead of the $1.65 reported. Leverage stays below the <2.5× debt-to-EBITDA target; no new quantified full-year outlook was given. Cash & Liquidity · Adjusted Net Income

Community sentiment · 612 votes

58% bullish

Bull 58%Neu 27%Bear 15%

AllSight

AllSight Pro

A buy-side analyst on every ticker — reading the whole market the second it moves.

It reads every public company's filing the instant it drops and hands you what it means — in plain English, before it's a headline.

The read itself

Not another feed. A buy-side analyst that never sleeps, on everything.

Whole-market breadthevery public company

Not the 20 names CNBC repeats. Every ticker that files — thousands of companies, one AI reading all of them.

Filed-to-decoded in secondsspeed

Filed 9:41:03, decoded 9:41:19. You've got the catalyst while the tape is still moving and the crowd's still on the headline.

Past the headlinedepth

What actually happened, the numbers that matter, how it sits vs what the Street expected, and what it sets up next.

Source-grounded & neutralrigor

Every read traces to the words in the actual filing — click to see them. A translation you can check, never a buy/sell call.

Zero effort to youconvenience

Plain English, one glance. Follow your stocks and the moment any of them files, it's in your pocket — no watching, no digging.

All of it, livePro

Free reads every session once it closes. Pro reads it the moment it files: the whole market, all day, every day.

And then — go deeper

From "what happened" to "is it worth it."

Cheap or dear?Where it trades vs its own valuation history.

The quality score, in fullAll five dimensions, ranked against its sector.

Structure & multi-year trendsRevenue, margins, cash — the hard numbers, decoded.

Insider activityWho inside the company is buying and selling.

Analyst price targetsWhere Wall Street says every name is headed.

The whole company, one pagePrice, ownership, the full read — on any ticker.

Hire your personal buy-side analyst.

Trade one usual slippage for a whole market's rhythm.

Free

forever

Every closed session, on the whole market. The live session and the deep company read stay Pro.

Monthly

$29/mo

billed monthly

Everything, live — every session the moment it files, plus the full company read. Flexible, month to month.

Best value · save 40%

Annual

$17.40/mo

$209 billed yearly

about one slippage a month

Same full access — the whole market live and every company — at the lowest price. 40% off the monthly.

Billed today. Powered by Stripe · AllSight never sees your card.

AllSight

Follow any company — we email you the moment it files, free!
Your watchlist saved to your account, on every device — free!

Limited-time offer

by Signing in NOW, claim your FREE 14-day Pro trial!

Every filing, live — decoded the instant it lands, zero delay from the SEC
Analyst-level reads — what changed, how it impacts, why it matters
The full read on every company — valuation, quality score, insider activity, analyst targets

That email doesn’t look right — try again.

OPKO asset sale fetches $722M as BioReference exits diagnostics

What to watch next

More Opko Health, Inc. news

Breaking down Wall Street's information edge.